The androgen
receptor plays a suppressive role in epithelial- mesenchymal transition of
human prostate cancer stem progenitor cells
Ma Zhifang*, Wei Liang, Zhang
Wei, Hao Bin, Tu Rui, Wu Nan and Zhang
Shuhai
- *Corresponding
author: Ma Zhifang zhifangma@163.com
BMC Biochemistry 2015, 16:13 doi:10.1186/s12858-015-0042-9
Published: 6 May 2015
Background To investigate the roles of androgen receptor
(AR) in epithelial- mesenchymal transition (EMT) in human prostate cancer stem
progenitor (S/P) cells isolated from LNCaP cell line. Methods The S/P cells
were obtained from LNCaP cell line through florescence-activated cell sorting
(FACS). AR was overexpressed in S/P cells through lentivirus. Western blot
assay was used to detect the EMT markers expression, such as E Cadherin, N
Cadherin, Vimentin and Snail. MTT assay, soft agar colony formation assay,
sphere formation assay and migration assay were used to investigate AR’s roles
in EMT of S/P cells. Cell signaling pathways associated with proliferation and
apoptosis of S/P cells were detected simultaneously. And S/P cells were treated
with in vitro combinatory use of LY 294002 (inhibitor of AKT signaling
molecules) with γ-TT and/or 5-AZA. Results Our data showed that S/P cells from
LNCaP had high EMT markers expression, more tumorigenesis and strong migration
ability. And in S/P cells overexpressed with AR, the expression of EMT markers
decreased. In addition, these cells had less proliferation ability,
tumorigenesis ability, self-renewal and migration ability. At the same time,
targeting S/P cells with AKT signaling pathway inhibitor LY29004 andγ-TT and/or
5-AZA could inhibit S/P cell’s proliferation and tumorigenesis. Conclusions Our
data suggest that AR played a negative role in EMT of PCa S/P cells, by
regulating AKT cell signaling pathway, which could be a new strategy to treat
castration resistant prostate cancer (CRPC).
The complete article is available as a provisional
PDF. The fully formatted PDF and HTML versions are in production. Tomado de envio de bcm
|
No hay comentarios:
Publicar un comentario